Black box warn­ing? No wor­ries, Valeant bills Siliq as the ‘low-cost’ pso­ri­a­sis al­ter­na­tive to ri­vals from No­var­tis, Eli Lil­ly

Valeant knew it wasn’t get­ting the best new in­jectable bi­o­log­ic for pso­ri­a­sis when it went bot­tom-fish­ing at As­traZeneca and picked up bro­dalum­ab for $270 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER